Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Doses and Dose Regimens of Evinacumab in Patients With Persistent Hypercholesterolemia Despite Maximally Tolerated Lipid Modifying Therapy
NCT03175367 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Doses and Dose Regimens of Evinacumab in Patients With Persistent Hypercholesterolemia Despite Maximally Tolerated Lipid Modifying Therapy
- Lead sponsor
- Regeneron Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 10, 2017
- Completion date
- December 14, 2020
- Enrollment
- 272 (actual)
- Sites
- 95
Conditions
As the registry lists them; a condition with its own page is linked.